Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HPGDS | O60760 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3024862 | 0.87 | CA1 (0.39) | RIPK1IDH1HDAC8CRBNMTNR1A | |
| SCHEMBL3012194 | 0.83 | RIPK1 (0.33) | RIPK1IDH1HDAC8 | |
| SCHEMBL3008126 | 0.78 | MTNR1A (0.34) | MAPK1MTNR1AMTNR1B | |
| SCHEMBL3030115 | 0.76 | KCNH2 (0.38) | RIPK1CRBN | |
| SCHEMBL3723303 | 0.75 | — | — | |
| SCHEMBL3023008 | 0.73 | HTR2C (0.32) | MTNR1AMTNR1BHTR2C | |
| SCHEMBL3663681 | 0.72 | PDE2A (0.37) | RIPK1MAPK1CRBNMTNR1AMTNR1B | |
| SCHEMBL3016282 | 0.72 | — | — | |
| SCHEMBL3026890 | 0.71 | KDM4C (0.40) | MTNR1AMTNR1BHTR2C | |
| SCHEMBL3724329 | 0.69 | KDM4C (0.31) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197679-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197679-A1 | COMPOUNDS | NRDC, MRPL21, NISCH | RIPK1 2693/4885IDH1 720/4885MAPK1 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.